Here are the latest figures on $OMDA (+0,3%) broken down with Gemini.
Key financial figures Q4 2025
- Turnover: USD 76 million
- Net income: USD 5 million (reaching the profit zone in the quarter)
- Adjusted EBITDA: USD 8 million
- Gross margin: 71% (non-GAAP: 73%)
Key financial figures for the full year (FY) 2025
- Turnover: USD 260 million (+53 % year-on-year)
- Net result: USD -13 million (net loss)
- Adjusted EBITDA: USD 6 million
- Gross margin: 66% (non-GAAP: 68%)
- Liquidity: USD 222 million (cash and cash equivalents)
Key operating figures & growth
- Number of members: 886,000 (+55 % year-on-year)
- GLP-1 sector: Over 150,000 members are supported with GLP-1 therapy.
Product development & strategy
- GLP-1 focus: Announcement of GLP-1 Flex Care for targeted support of this patient group.
- AI integration: Introduction of the OmadaSpark and Meal Map tools (2025).
- Portfolio expansion: Launch of Omada for Cholesterol in February 2026.
- Management focus: CEO Sean Duffy emphasizes transition to profitability, scaling through AI and expansion of GLP-1 companion programs.
Outlook FY 2026
- Sales forecast: USD 312 million to USD 322 million
- Adjusted EBITDA: USD 7 million to USD 15 million
